{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:36:29Z","timestamp":1761885389293,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.acuroe.2022.09.002","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T13:31:17Z","timestamp":1665063077000},"page":"1-3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Editorial commentary on: \u201cReduced vs full-dose BCG therapy in bladder cancer: A systematic review and meta-analysis\u201d"],"prefix":"10.1016","volume":"47","author":[{"given":"D.M.","family":"Carrion","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Soria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"del Giudice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuroe.2022.09.002_bib0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.acuro.2022.06.001","article-title":"Dosis reducida vs. dosis completa de BCG en el c\u00e1ncer de vejiga: revisi\u00f3n sistem\u00e1tica y metaan\u00e1lisis","volume":"47","author":"Verri","year":"2023","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.acuroe.2022.09.002_bib0010","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.acuro.2017.10.003","article-title":"Safety and efficacy of various strains of bacille Calmette-Gu\u00e9rin in the treatment of bladder tumours in standard clinical practice","volume":"42","author":"Unda-Urzaiz","year":"2018","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.acuroe.2022.09.002_bib0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2022.09.002_bib0020","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.acuro.2019.02.006","article-title":"Validation of the CUETO scoring model for predicting recurrence and progression in T1G3 urothelial carcinoma of the bladder","volume":"43","author":"Krajewski","year":"2019","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.acuroe.2022.09.002_bib0025","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.acuro.2013.04.002","article-title":"Treatment of non muscle invasive bladder tumor related to the problem of bacillus Calmette-Guerin availability. Consensus of a Spanish expert\u2019s panel. Spanish Association of Urology","volume":"37","author":"Fern\u00e1ndez-G\u00f3mez","year":"2013","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.acuroe.2022.09.002_bib0030","first-page":"35","article-title":"Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR)","volume":"14","author":"Musat","year":"2022","journal-title":"Clin Outcomes Res CEOR"},{"key":"10.1016\/j.acuroe.2022.09.002_bib0035","unstructured":"Kazt A. Sanofi\u2019s Halt of BCG Production Worries Bladder Cancer Patients and Urologists. Consulted on July 18th, 2022. Available at: https:\/\/www.onclive.com\/view\/sanofis-halt-of-bcg-production-worries-bladder-cancer-patients-and-urologists."},{"key":"10.1016\/j.acuroe.2022.09.002_bib0040","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"Grimm","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2022.09.002_bib0045","doi-asserted-by":"crossref","first-page":"e2176","DOI":"10.1097\/MD.0000000000002176","article-title":"Low-dose versus standard dose of bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis","volume":"94","author":"Zeng","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.acuroe.2022.09.002_bib0050","doi-asserted-by":"crossref","first-page":"e8300","DOI":"10.1097\/MD.0000000000008300","article-title":"Dose, duration and strain of bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer","volume":"96","author":"Quan","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.acuroe.2022.09.002_bib0055","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4111\/icu.20210340","article-title":"Low-dose versus standard-dose bacille Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer: systematic review and meta-analysis of randomized controlled trials","volume":"63","author":"Choi","year":"2022","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.acuroe.2022.09.002_bib0060","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3390\/cancers14040887","article-title":"Compared efficacy of adjuvant intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): a propensity score matched analysis","volume":"14","author":"Del Giudice","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.acuroe.2022.09.002_bib0065","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1007\/s00432-021-03571-0","article-title":"Efficacy of three BCG strains (Connaught, TICE and RIVM) with or without secondary resection (re-TUR) for intermediate\/high-risk non-muscle-invasive bladder cancers: results from a retrospective single-institution cohort analysis","volume":"147","author":"Del Giudice","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.acuroe.2022.09.002_bib0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.acuro.2020.08.003","article-title":"Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC)","volume":"45","author":"\u00c1lvarez-Maestro","year":"2021","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.acuroe.2022.09.002_bib0075","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.3390\/cancers14133073","article-title":"BCG in bladder cancer immunotherapy","volume":"14","author":"Jiang","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578622001019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578622001019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:15:30Z","timestamp":1761880530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173578622001019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2173578622001019"],"URL":"https:\/\/doi.org\/10.1016\/j.acuroe.2022.09.002","relation":{},"ISSN":["2173-5786"],"issn-type":[{"type":"print","value":"2173-5786"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Editorial commentary on: \u201cReduced vs full-dose BCG therapy in bladder cancer: A systematic review and meta-analysis\u201d","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuroe.2022.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2022.07.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.acuroe.2022.08.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}